Elsevier

Human Pathology

Volume 22, Issue 12, December 1991, Pages 1232-1239
Human Pathology

Original contribution
Lobular neoplasia of the breast: Higher risk for subsequent invasive cancer predicted by more extensive disease

https://doi.org/10.1016/0046-8177(91)90105-XGet rights and content

Abstract

We have stratified the cancer risk implications of lobular pattern in situ neoplasias of the breast by separating marked examples of this histologic spectrum (lobular carcinoma in situ [LCIS]) from lesser examples (atypical lobular hyperplasia). The lesser-developed examples have been shown previously to have a lower relative risk (RR) of later invasive carcinoma of the breast (IBC). Forty-eight examples of LCIS were found in 10,542 otherwise benign breast biopsies, representing an incidence of 0.5%. Nine patients were excluded from follow-up because of bilateral mastectomy within 6 months of entry biopsy, IBC within 6 months of entry biopsy, or prior IBC. Follow-up of the remaining 39 patients was complete, averaged 18 years, and revealed an RR of subsequent IBC of 6.9 (P < .00001). Average overall follow-up for LCIS patients was 19 years; it was 25 years for those alive and free of IBC at the time of their follow-up interview. Neither family history of IBC nor post-menopausal estrogen therapy further affected risk. The absolute risk of IBC after LCIS was 17% at 15 years (adjusted for withdrawals), and the RR was 8.0 in the first 15 years of follow-up compared with the general population. An analysis based on a time-dependent hazards model found that during the first 15 years following biopsy women with LCIS had 10.8 times the risk of breast cancer compared with biopsied women of comparable age who lacked proliferative disease. Some previously published articles reporting lobular neoplasia (LN) suggest that those series with the greatest incidences of LN (whether termed LN or LCIS) have the lowest RR of subsequent breast cancer. Those series with higher incidences of LN include less well-developed histologic patterns of LN (atypical lobular hyperplasia). We conclude that our study of LN and studies performed by others support the higher risk of IBC after histologically flagrant examples (LCIS, about nine times higher) and a relatively lower but definable risk after more histologically subtle examples (atypical lobular hyperplasia, four to five times lower). This relative cancer risk is probably not constant over more than 15 years; thus, cancer risk 15 to 25 years after initial diagnosis of LCIS is uncertain.

References (25)

  • DL Page et al.

    Ductal involvement by cells of atypical lobular hyperplasia in the breast: A long-term follow-up study of cancer risk

    Hum Pathol

    (1988)
  • FW Foote et al.

    Lobular carcinoma in situ

    Am J Pathol

    (1941)
  • CD Haagensen et al.

    Lobular neoplasia (so-called lobular carcinoma in situ) of the breast

    Cancer

    (1978)
  • PP Rosen et al.

    Lobular carcinoma in situ of the breast: Detailed analysis of 99 patients with average follow-up of 24 years

    Am J Surg Pathol

    (1978)
  • RW McDivitt et al.

    In situ lobular carcinoma: A prospective follow-up study indicating cumulative patient risks

    JAMA

    (1967)
  • WD Dupont et al.

    Risk factors for breast cancer in women with proliferative breast disease

    N Engl J Med

    (1985)
  • DL Page et al.

    Atypical hyperplastic lesions of the female breast. A long-term follow-up study

    Cancer

    (1985)
  • DL Page et al.

    Epithelial hyperplasia

  • S Greenland

    Quantitative methods in the review of epidemiologic literature

    Epidemiol Rev

    (1987)
  • CR Rao

    Linear Statistical Inference and Its Applications

  • SJ Cutler et al.

    Third National Cancer Survey: Incidence Data

  • JM Dixon et al.

    Infiltrating lobular carcinoma of the breast

    Histopathology

    (1982)
  • Cited by (0)

    Supported by grants R01-CA-31698, R01-CA-40517, R01-CA-46492, and R01-CA-28223 from the National Cancer Institute and ACS RD 222 from the American Cancer Society.

    Presented in part at the US-Canada Division of the International Academy of Pathology, Washington, DC, 1988.

    View full text